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A novel score in the prediction of rhythm outcome after ablation of 
atrial fibrillation: The SUCCESS score
Introduction
Atrial fibrillation (AF) is the most common type of arrhythmia, 
affecting >1% of all adults worldwide and causing a significant 
impact on public health (1, 2). Over the last decades, catheter ab-
lation has become an established form of treatment, especially 
in patients where medical therapy is not sufficient for rhythm 
stabilization or not tolerated due to side effects (3). Treatment of-
ten includes anticoagulation therapy owing to an increased risk 
of stroke or systemic embolic events in patients with AF (4, 5). 
Well-established score systems (CHADS2, CHA2DS2-VASc, and 
R2CHADS2) are commonly used to estimate the risk of cardioem-
bolic events (6-8).
Few studies have aimed to assess these score systems and/
or other risk factors, such as enlargement of the left atrium (LA), 
to predict rhythm outcome after catheter ablation (9–12). How-
ever, these studies showed inconsistent results when it came to 
reproducing a similar significant predictive value of the studied 
scores. Hence, there are currently no strong recommendations 
suggesting the use of CHADS2 or CHA2DS2-VASc score rather 
than other score systems (13, 14).
The aim of the present study was to assess which risk fac-
tors and score systems have a predictive value for the rhythm 
outcome after catheter ablation in our patient cohort of a single 
tertiary care center in Switzerland. The study focuses primar-
ily on four different score systems (CHADS2, CHA2DS2-VASc, 
R2CHADS2, and APPLE score) and secondarily on the specific 
components of those scores independently.
Methods
Study population
All patients suffering from symptomatic AF (either paroxys-
mal or persistent) undergoing one or multiple catheter ablations 
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at our institution between June 2009 and February 2014 were in-
cluded in the study. In accordance with the current guidelines, 
paroxysmal AF was defined as episodes terminating within 7 
days, whereas persistent AF was defined as lasting >7 days (15). 
Data, including sex, age, type of AF, number of previous ablations, 
history of congestive heart failure, hypertension, diabetes mel-
litus, history of stroke or transient ischemic attack (TIA), coro-
nary artery disease (CAD), size of the LA, ejection fraction (EF) of 
the left ventricle, structural heart disease, creatinine blood level, 
height, and weight, on comorbidities and risk factors were col-
lected in all patients.
Scores
The following data were used to calculate different scores: 
CHADS2 score (1 point for congestive heart failure, hypertension, 
age ≥75 years, and diabetes mellitus and 2 points for history of 
stroke or TIA; range from 0 to 6) (6), CHA2DS2-VASc score (1 point 
for congestive heart failure, hypertension, age 65–74 years, dia-
betes mellitus, vascular disease, and female sex and 2 points for 
age ≥75 years and history of stroke or TIA; range from 0 to 10) 
(7), R2CHADS2 score (CHADS2 score plus an additional 2 points 
for creatinine clearance [estimated glomerular filtration rate 
(eGFR)] <60 mL/min; range from 0 to 8) (8), APPLE score (1 point 
for age >65 years, persistent AF, eGFR <60 mL/min/1.73 m2, LA 
diameter ≥43 mm, and left ventricular EF <50%; range from 0 to 
5) (13), and eGFR was estimated using the MDRD-Study-Formula: 
eGFR=175*serum creatinine−1.154*Age−0.203*[1.210 if black]*[0.742 
if female]. However, the factor 1.210 was not applied because 
the race of the patients was not part of the registered data in the 
present study (16).
Ablation
Radiofrequency (RF) energy was used for catheter ablation 
in most cases. Only in a few cases was an alternative source 
of energy used (cryoenergy, n=6 and laser light, n=2). The tech-
nique used in all patients consisted of a wide-area circumferen-
tial point-by-point RF ablation of the ipsilateral pulmonary veins 
ostia. The acute success was confirmed by the achievement of 
the procedural endpoint that consisted in electrical isolation 
of all pulmonary veins from the LA. This was demonstrated by 
circular mapping of each pulmonary vein showing the entrance 
and exit block. Additional linear lesions or substrate modifica-
tions were performed at the discretion of the operator in patients 
suffering from persistent AF (17–21).
Definition of success
After the last follow-up, patients were divided into three 
groups based on their outcome. “Success” was defined as lack 
of AF lasting >30 s in Holter electrocardiographies (ECGs) and 
absence of arrhythmia symptoms. “Partial success” was de-
fined as reduction of AF duration >90% in patients without clini-
cally symptomatic AF. This definition is based mainly on Holter 
ECGs and was included because even though these patients 
do not meet the criteria of the “success” category, they do not 
qualify for another ablation. “Failure” was defined as any result 
not meeting the criteria of the previous two groups, represent-
ing recurrence of AF. Antiarrhythmic drugs were used after the 
intervention if required at the discretion of the treating physi-
cian. However, the use of antiarrhythmic drugs was not taken 
into consideration for the definition of success.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation (SD) or median with interquartile ranges and were 
compared using the Student’s t-test or Mann-Whitney U test as 
appropriate. Categorical data are presented as frequency (per-
centages) and were compared using the Fisher’s exact or chi-
square test. Variables with a significant odds ratio (OR) (p<0.05) 
in a univariate analysis model for the prediction of the primary 
outcome were included in an Enter-Method multivariate logis-
tic regression model to determine independent predictors of the 
studied outcome. Calibration was determined by the Hosmer–
Lemeshow goodness-of-fit test. For discrimination, the C sta-
tistics and receiver operating characteristic (ROC) curves were 
constructed to assess and compare the ability of the CHADS2, 
CHA2DS2-VASc, R2CHADS2, APPLE, and SUCCESS scores for the 
prediction of the recurrence of AF. All probability values and con-
fidence intervals (CIs) were two-sided. A p-value of <0.05 was 
considered significant, a p-value of <0.1 and >0.05 was consid-
ered a trend, and all tests were two-tailed. All statistical analy-
ses were performed using SPSS version 23.0 software (SPSS 
Inc., Chicago, IL, USA).
Ethical standards
The Local Ethics Committee approved the study in accor-
dance with the ethical standards of the Declaration of Helsinki.
Results
Patient characteristics
The cohort of the present study consisted of 192 patients 
undergoing a total of 265 catheter ablations. A single procedure 
was performed in 128 (67%) patients, and multiple procedures 
were performed in 64 (33%) patients, with 9 (5%) patients requir-
ing a total of three ablations. The mean number of procedures 
per patient was 1.38±0.57. Of the patients, 146 (76%) were men, 
and 46 (24%) were women. Out of the 192 patients, 116 (60%) 
were diagnosed with paroxysmal AF, whereas 76 (40%) were 
diagnosed with persistent AF. The mean age at the time of the 
procedure was 61.8±9.2 years, and the mean time between first 
diagnosis and ablation was 5.8±4.3 years. All ablations were per-
formed between 2009 and 2014. Table 1 summarizes the patient 
characteristics and risk factors. Table 2 shows the distribution 
within the different score systems.
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Follow-up
Follow-up examinations were performed at 3, 6, 12, and 24 
months, which included symptom assessment and ECG monitor-
ing. These findings were used for evaluating the success of the 
treatment of each patient.
In 83% of the patients, Holter ECGs were available during 
follow-up. For the remaining patients, outcome was evaluated 
by ECG recordings and symptom assessment. The mean follow-
up duration was 19 (SD±12; range 3–55) months, with 142 (74%) 
patients being assessed at least 12 months and 70 (36%) patients 
at least 24 months after the procedure.
Table 1. Patient characteristics
Characteristics
No. of patients 192
No. of ablations 265
Ablations per patient 1.37±0.58
Patients with one ablation 128 66.67%
Patients with two ablations 55 28.65%
Patients with three ablations 9 4.69%
Time to procedure (years) 5.81±4.33
Male 146 76.04%
Female 46 23.96%
Age (years) 61.8±9.19
Paroxysmal AF 116 60.42%
Persistent AF 76 39.58%
Risk factors
Previous procedures 64 33.33%
Heart failure 10 5.21%
Hypertension 92 47.92%
Age 65–74 years 64 33.33%
Age >74 years 16 8.33%
Diabetes mellitus 16 8.33%
History of stroke/TIA 20 10.42%
CAD 20 10.42%
LA size (mm) 43.7±6.86
LA size >42 mm 103 53.65%
EF (%) 58.5±8.06
EF <50% 22 11.46%
Structural heart disease 13 6.77%
Creatinine (µmol/L) 91.7±18.20
eGFR (mL/min/1.73 m2) 71.3±16.84
Renal dysfunction 52 27.08%
Weight (kg) 85.9±15.97
Height (cm) 176.0±9.14
BMI (kg/m2) 27.7±4.23
AF – atrial fibrillation; BMI – body mass index; CAD – coronary artery disease;  
eGFR – estimated glomerular filtration rate; EF – ejection fraction;  LA – left atrium;  
TIA – transient ischemic attack
Table 2. Scores
CHADS2 score
0 point 77 40.10%
1 point 75 39.06%
2 points 23 11.98%
3 points 15 7.81%
4 points 2 1.04%
Mean±SD 0.91±0.96
CHA2DS2-VASc score
0 point 51 26.56%
1 point 46 23.96%
2 points 43 22.40%
3 points 28 14.58%
4 points 17 8.85%
5 points 6 3.13%
6 points 1 0.52%
Mean±SD 1.67±1.44
R2CHADS2 score
0 point 64 33.33%
1 point 46 23.96%
2 points 30 15.63%
3 points 41 21.35%
4 points 7 3.65%
5 points 3 1.56%
6 points 1 0.52%
Mean±SD 1.45±1.36
APPLE score
0 point 32 16.67%
1 point 54 28.13%
2 points 59 30.73%
3 points 30 15.63%
4 points 14 7.29%
5 points 3 1.56%
Mean±SD 1.73±1.21
SUCCESS score
0 point 27 14.06%
1 point 40 20.83%
2 points 54 28.13%
3 points 39 20.31%
4 points 19 9.90%
5 points 13 6.77%
Mean±SD 2.11±1.41
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Rhythm outcome
Out of all 192 cases, 139 (72%) were classified as “success”, 
21 (11%) as “partial success”, and 32 (17%) as “failure”, leading 
to a total of 160 (83%) patients being treated “successfully” or at 
least “partial successfully”. A subgroup analysis was performed 
for the 70 (36%) patients who were followed up for at least 24 
months after the procedure. In this subgroup, 41 (59%) patients 
were in paroxysmal AF, and 29 (41%) patients were in persistent 
AF. Of the cases, 43 (61%) were classified as “success”, 16 (23%) 
as “partial success”, and 11 (16%) as “failure”. In conclusion, 
59 (84%) out of the 70 cases were considered a “success” or 
“partial success” after a follow-up of 2 years.
During the duration of our study, 3 (1.6%) patients showed 
left atrial flutter. All three patients returned to sinus rhythm ei-
ther spontaneously (one case) or after electrical cardioversion 
(two cases). All other arrhythmia recurrences were AF. Early 
recurrence AF within the 3-month blanking period was not con-
sidered.
Predictors for recurrence of AF after catheter ablation
During the follow-up period, 32 (17%) patients showed re-
currence of AF. The primary results showed that there was no 
significantly higher incidence or prevalence of heart failure, hy-
pertension, diabetes mellitus, or CAD in patients with AF recur-
rence than in those with normal sinus rhythm. However, a trend 
was observable for persistent AF (p-value 0.068), LA size (0.068), 
time to procedure (0.066), and previous ablations (0.098) (Table 3).
Of the different scores, only the APPLE score demonstrated a 
significant predictive value for recurrence of AF in the univariate 
logistic regression analysis (OR 1.485, 95% CI 1.075–2.052, p-value 
0.017), whereas the CHADS2, CHA2D2-VASc, and R2CHADS2 scores 
were all not significant predictors for rhythm outcome (Table 4).
Table 3. Predictors of atrial fibrillation
Variables Study population                                               Arrhythmia recurrences
 n=192 No (n=160) Yes (n=32) P-value
Age (years) 61.77±9.188 61.7±9.1 62.1±9.8 0.848
Males (%) 76 76.7 72.4 0.640
Heart failure (%) 5.2 4.9 6.9 0.649
Persistent AF (%) 39.6 36.8 55.2 0.068
Hypertension (%) 47.9 47.2 51.7 0.691
Diabetes (%) 8.3 9.2 3.4 0.474
History of stroke/TIA (%) 10.4 10.4 10.3 1.000
CAD (%) 10.4 9.8 13.8 0.513
LA size >42 mm (%) 53.6 50.9 69 0.105
LA size (mm) 43.67±6.8 43.3±6.8 45.9±6.8 0.068
EF <50% (%) 11.5 10.4 17.2 0.339
EF (%) 58.52±8.06 58.7±7.5 57.3±10.9 0.420
SHD (%) 7.3 6.6 11.1 0.419
Creatinine (µmol/L) 91.74±18 91.1±17.2 95.1±22.8 0.279
eGFR <60 mL/min/1.73 m2 (%) 27.1 25.2 37.9 0.175
eGFR (mL/min/1.73 m2) 71.25±16.8 71.8±16.9 68.3±16.8 0.306
Previous ablation (%) 33.3 31.3 44.8 0.199
BMI (kg/m2) 27.67±4.23 27.6±4.4 27.8±3.5 0.844
Time to procedure (years) 5.81±4.3 5.6±4.3 7.2±4.5 0.066
Total ablations 1.38±0.57 1.3±0.5 1.6±0.7 0.098
CHADS2 score 0.91±0.96 0.9±1.0 0.9±0.8 0.881
CHA2D2-VASc score 1.67±1.43 1.6±1.5 1.8±1.3 0.608
R2CHADS2 score 1.45±1.86 1.4±1.4 1.7±1.3 0.302
APPLE score 1.73±1.2 1.6±1.7 2.2±1.4 0.014
AF – atrial fibrillation; BMI – body mass index; CAD – coronary artery disease; eGFR – estimated glomerular filtration rate; EF – ejection fraction;  LA – left atrium; TIA – transient 
ischemic attack; SHD - structural heart disease
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The APPLE score also showed a better predictive value us-
ing the ROC curve analysis [area under the curve (AUC) 0.620, 
p-value 0.040] than CHADS2 (AUC 0.535, p-value 0.548), CHA2D2-
VASc (AUC 0.542, p-value 0.472) and R2CHADS2 (AUC 0.570, p-
value 0.228). Nevertheless, the difference in AUC did not reach 
statistical significance (p-value >0.05) (Fig. 1).
The distribution of the cohort within the APPLE score for 0, 1, 
2, and ≥3 points was 17%, 28%, 31%, and 24%, respectively. The 
rates for AF recurrence for these subgroups were 6% (APPLE 
score 0), 15% (1), 14% (2), and 31% (≥3) (p=0.227) (Fig. 2). The 
risks (OR) for recurrence of AF were 2.609 (95% CI 0.518–13.133, 
p=0.245) (APPLE score 1), 2.353 (95% CI 0.469–11.816, p=0.299) 
(APPLE score 2), and 4.583 (95% CI 0.942–22.310, p=0.059) (APPLE 
score ≥3) compared with a score of 0.
After this initial analysis, we performed a multivariate analy-
sis, including the APPLE score and the two risk factors with the 
highest significance from the logistic regression analysis that 
were previous ablations (OR 1.917, 95% CI 1.030–3.569, p-value 
0.040) and time to procedure (OR 1.082, 95% CI 0.994–1.179, p-
value 0.070). In this analysis, both the APPLE score (OR 1.527, 
95% CI 1.082–2.153, p-value 0.016) and previous ablations ≥2 (OR 
5.831, 95% CI 1.356–25.066, p-value 0.018) remained significant. 
We also generated a multivariate binary regression model cor-
rected for three significant confounding variables with an appro-
priate fit (H and L test: chi-square 4.039, p-value 0.854).
These findings showed that the number of previous ablations 
appears to have a significant impact on the rhythm outcome. In 
order to confirm this observation, we created a new score sys-
tem based on the APPLE score by adding a point for every previ-
ous ablation. We called this novel score SUCCESS [Severity of 
AF type (persistent AF), Unsuccessful previous ablations (1 point 
per ablation), Creatinine Clearance (eGFR <60 mL/min/1.73 m2), 
Elderly (>65 years), Size of LA (≥43 mm), Systolic left ventricular 
EF (<50%)].
Table 4. Odds ratio
Scores OR 95% CI P-value
LA size (mm) 1.056 0.995-1.120 0.071
EF (%) 0.980 0.934-1.029 0.419
Persistent AF 2.113 0.951-4.693 0.066
eGFR (mL/min/1.73 m2) 0.987 0.963-1.012 0.305
Time to procedure (years) 1.082 0.994-1.179 0.070
Previous ablations 1.917 1.030-3.569 0.040
CHADS2 score 1.032 0.686-1.552 0.880
CHA2D2-VASc score 1.074 0.819-1.407 0.607
R2CHADS2 score 1.160 0.876-1.536 0.301
APPLE score 1.485 1.075-2.052 0.017
AF – atrial fibrillation; eGFR – estimated glomerular filtration rate; EF – ejection 
fraction;  LA – left atrium; OR - odds ratio
Figure 3. ROC curve 2. Comparison between all scores including 
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We compared those two score systems using the ROC curve 
analysis. The newly formed SUCCESS score demonstrated an 
improvement (AUC 0.657) compared with the APPLE score (AUC 
0.620), which was not significant however (p-value 0.219) (Fig. 3). 
Furthermore, the SUCCESS score remained a significant predic-
tor of recurrence despite the addition of partial success to re-
currence [outcome of recurrence including partial success: OR 
1.453 (95% CI 1.146–1.843), p-value 0.002 and outcome of recur-
rence excluding partial success: OR 1.539 (95% CI 1.145–2.051), 
p-value 0.003].
Discussion
To the best of our knowledge, this is the first study comparing 
the predictive value for rhythm outcome after catheter ablation 
in patients with AF of all four scores CHADS2, CHA2DS2-VASc, 
R2CHADS2, and APPLE. Among these score systems, only the 
APPLE score was a significant predictor for rhythm outcome in 
our patient cohort. The newly introduced SUCCESS score might 
predict outcome even better.
The most recently reported APPLE scoring system by Kornej 
et al. (13) showed to be capable of predicting rhythm outcome 
in patients after first and repeated ablation procedures and has 
proven to be superior to the previously reported scoring sys-
tems (22). In our study, we obtained very similar results to those 
by Kornej et al. (13) who introduced the novel APPLE score. Us-
ing the ROC curve analysis, we received an AUC of 0.620 [Kornej 
et al. (13): 0.634]. The distribution of patients within the APPLE 
score of the two cohorts was comparable (APPLE scores of 0, 
1, 2, and ≥3: 17%, 28%, 31%, and 25%, respectively) [Kornej et 
al. (13): 21%, 34%, 31%, and 25%, respectively], as was the risk 
(OR) for arrhythmia recurrence [APPLE scores of 1, 2, or ≥3: 2.61 
(95% CI 0.52–3.13), 2.35 (95% CI 0.47–11.81), and 5.58 (95% CI 
0.94–22.31), respectively] [Kornej et al. (13): 1.73 (95% CI 1.17–
2.55), 2.79 (95% CI 1.90–4.12), and 4.70 (95% CI 3.03–7.30), re-
spectively]. While Kornej et al. (13) demonstrated the predictive 
value of the APPLE score in patients undergoing their first abla-
tion and also for repeated ablations (22), they did not include 
previous interventions as a factor in their score. We sought to 
further improve the predictive value of this score by awarding 
an additional point for every previously performed ablation in 
the patient’s medical history, which was the most significant 
specific risk factor in our study. This newly created SUCCESS 
score performed slightly better in the ROC curve analysis than 
the APPLE score (AUC 0.657 vs. 0.620) (Fig. 3). However, this im-
provement did not reach statistical significance (p-value 0.219). 
This might be due to the low number of AF recurrences [32] 
in our cohort of 192 patients. The predictive value of the SUC-
CESS score proposed in the present study certainly needs to be 
tested in a larger cohort.
Previously, several studies evaluated predictors for rhythm 
outcome after catheter ablation in patients with AF. For the spe-
cific risk factors, a meta-analysis found that the most signifi-
cant variables were persistent AF, valvular AF, size of LA >50 
mm, and recurrence of AF within 30 days (11). However, the two 
most significant specific risk factors of our results (previous ab-
lations and time to procedure) were not analyzed in this meta-
analysis. A recent study reported that a shorter period between 
diagnosis and ablation of AF increases the rate of success of 
the procedure (23). The predictive value of the number of pre-
vious ablations for prediction rhythm outcome in patients with 
AF has not been evaluated yet. However, there are data avail-
able comparing the success rates of first-time ablations and re-
peated ablations. In contrast to our findings, data suggest that 
these success rates remain unchanged, independently of the 
total count of ablations (14), or that they increase with each ad-
ditional procedure (24, 25).
CHADS2 and CHA2DS2-VASc scores are the two most ex-
tensively studied scores. Both are primarily used to determine 
the usefulness of anticoagulation in patients with AF. Although 
they appear to be associated with recurrence after ablations as 
proposed by multiple studies, their predictive value is, however, 
modest (9, 12, 14, 25, 26). Fewer studies have evaluated the role of 
novel scores, such as the R2CHADS2 score, which was created to 
assess the risk of stroke and systemic embolism in patients with 
AF (8). R2CHADS2 appeared to have a better predictive value than 
the CHADS2 and CHA2DS2-VASc score systems (9).
We did not include other scoring systems because they ei-
ther had no predictive value for rhythm outcome [HATCH (27, 
28)], included early recurrence and therefore were unpractical 
for baseline prediction [BASE-AF (29) and MB-Later (30)] or were 
used for patients who underwent repeated ablations [ALARMEc 
(31)].
Since the SUCCESS score is mainly based on the existing 
APPLE score, it also shares its advantages (13). Its composi-
tion is based on the results of a multivariate analysis of a co-
hort of 2067 patients (9). Combining the significant, indepen-
dent predictors of AF recurrence of that study (persistent AF, 
renal insufficiency, age, size of LA, and reduced EF) with our 
own results (previous number of ablation procedure) results in 
a score system, which is easy to use and consists of param-
eters routinely assessed in patients, making it convenient for 
clinical practice. Further studies with larger cohorts should be 
conducted to confirm our findings.
Study limitations
This was a single-center cohort. The main limitation of the 
present study is the small number of patients, which is not suf-
ficient to establish a novel scoring system on its own. However, 
we suggest that by adding an additional point for previously per-
formed ablations to the APPLE score might improve its predic-
tive value and should be tested in larger cohorts. Furthermore, as 
arrhythmia recurrences might be underdetected, further studies 
with continuous rhythm monitoring are needed to confirm these 
findings.
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Conclusion
Both the APPLE and the novel SUCCESS scores are superior 
to the CHADS2, CHA2DS2-VASc, and R2CHADS2 scores in predict-
ing the recurrence of atrial tachyarrhythmia after catheter ab-
lation in patients with AF. The SUCCESS score appears to have 
a higher predictive value than the APPLE score. Further studies 
with larger number of patients should be performed to confirm 
our findings.
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